Dasatinib monotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia with pulmonary infection in induction remission: A case report and review of the literature

Medicine
Cheng ZhangXi Zhang

Abstract

There is currently no clinical standard for induction therapy in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph ALL). Chemotherapy in combination with tyrosine kinase inhibitors (TKIs) recognized as the first line of therapy to induce remission in Ph ALL patients; however, both the infectious and non-infectious toxicities remain high and lead to early excessive treatment-related mortality (TRM). Single-agent TKI "monotherapy" may reduce toxicity and TRM; however, TKI induction monotherapy and its effectiveness in the induction of remission in newly diagnosed Ph ALL has yet to be investigated. A 59-year-old man who was newly diagnosed Ph ALL with 93% blast cells and a t (9, 22) karyotype. But the patient also suffered from pulmonary infection, including fever and dyspnea. The patient was newly diagnosed with Ph ALL with pulmonary infection. The patient received oral dasatinib monotherapy (100 mg qd) for 28 days as induction therapy. The patient reached complete remission with negative minimal residual disease detected by real-time quantitative polymerase chain reaction after induction therapy for 28 days. This is the first report on the use of dasatinib monotherapy in the absence of other drug...Continue Reading

References

Oct 21, 2015·Journal of the National Comprehensive Cancer Network : JNCCN·Joseph C AlvarnasCourtney Smith
Apr 29, 2016·Blood·Philippe RousselotUNKNOWN European Working Group on Adult ALL (EWALL) group
Aug 6, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Federico LussanaAlessandro Rambaldi
Oct 17, 2017·Journal of the American Academy of Dermatology·Sherry H YuJonathan I Silverberg

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.